SCHEMBL3019849

SCHEMBL3019849

CCc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cccc(Br)c4)CC3)n2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM1L O00429 2/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
MAPK1 P28482 1/20 0.34
DRD2 P14416 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
KIF18A Q8NI77 2/20 0.33
OGA O60502 1/20 0.33
TP53 P04637 1/20 0.33
HTR2A P28223 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
ALDH1A1 P00352 1/20 0.32
MBTD1 Q05BQ5 1/20 0.32
L3MBTL3 Q96JM7 1/20 0.32
LDHA P00338 1/20 0.32
LDHB P07195 1/20 0.32
GPR6 P46095 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016805 0.93 HTR2A (0.35) NPC1RAB9AKMT2AMEN1LMNA
SCHEMBL3007182 0.93 GBA1 (0.38) DNM1LNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL3001014 0.92 HTR2A (0.41) DNM1LNPC1RAB9AKMT2AMEN1
SCHEMBL3003523 0.91 HTR2A (0.38) DNM1LNPC1RAB9AKMT2AMEN1
SCHEMBL3008542 0.91 MAPT (0.36) DNM1LNPC1RAB9ADRD2SMN1; SMN2
SCHEMBL3017067 0.90 RORC (0.37) NPC1RAB9AKMT2AMEN1LMNA
SCHEMBL3014895 0.90 MAPT (0.39) NPC1RAB9ALMNAMAPK1SMN1; SMN2
SCHEMBL3007647 0.89 KMT2A (0.34) DNM1LNPC1RAB9AKMT2AKIF18A
SCHEMBL3014910 0.89 GPR6 (0.42) DNM1LNPC1RAB9AKMT2AMEN1
SCHEMBL3264261 0.89 RAB9A (0.39) DNM1LNPC1RAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA DNM1L 180/4885NPC1 15/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.